ramucirumab
Sign in to saveAlso known as IMC-1121B, 1121B
Ramucirumab(), sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer. Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. Ramucirumab was developed by ImClone Systems.
Key facts
- Drug.S
- 46
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 464380023
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- VEGFR2 (KDR)
- Drug.tradename
- Cyramza
- Drug.MedlinePlus
- a614026
- Drug.DailyMedID
- Ramucirumab
- Drug.routes_of_administration
- Intravenous infusion
- Drug.class
- Antineoplastic
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FG02
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Research
1,590 papers- Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.The New England journal of medicine · 2025
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.Lancet (London, England) · 2014
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.The Lancet. Oncology · 2014
- Ramucirumab: A Review in Hepatocellular Carcinoma.Drugs · 2020
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet (London, England) · 2014
via PubMed
~5 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Pharmacology
- Mechanism of action
- History
- Clinical trials
- References
Ramucirumab(), sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer. Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. Ramucirumab was developed by ImClone Systems.
== Medical uses == Ramucirumab is indicated for the treatment of gastric cancer, colorectal cancer, non-small cell lung cancer, and hepatocellular carcinoma.
Excerpted from Wikipedia’s “ramucirumab” article, available under the CC BY-SA 4.0 licence.